FocalTherics (NASDAQ:FOCL) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded FocalTherics from “Hold” to “Sell,” while the broader analyst consensus remains “Hold” with an average price target of $7.75.
• FocalTherics reported quarterly EPS of -$0.39, missing the $-0.20 consensus estimate, on revenue of $13.2 million; analysts expect a full-year loss of approximately $0.78 per share.
• The stock opened at $4.76 and was up 2.8%, with a market capitalization of $178.4 million; institutional investors and hedge funds own 62.74% of shares.

FocalTherics (NASDAQ:FOCL - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of FocalTherics in a report on Tuesday, June 2nd. Piper Sandler restated a "neutral" rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday. Finally, Mizuho set a $15.00 price target on FocalTherics and gave the stock an "outperform" rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, FocalTherics presently has a consensus rating of "Hold" and a consensus target price of $7.75.

FocalTherics Trading Up 2.8%

FOCL opened at $4.76 on Friday. The company has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The company has a fifty day moving average of $5.39. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. On average, equities research analysts predict that FocalTherics will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On FocalTherics

Large investors have recently modified their holdings of the business. Rock Springs Capital Management LP grew its holdings in shares of FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company's stock valued at $5,126,000 after acquiring an additional 91,500 shares in the last quarter. Flax Pond Capital LLC bought a new stake in FocalTherics during the fourth quarter worth about $2,623,000. Leonteq Securities AG bought a new stake in FocalTherics during the fourth quarter worth about $313,000. Kovack Advisors Inc. acquired a new position in FocalTherics during the fourth quarter valued at approximately $53,000. Finally, Lido Advisors LLC acquired a new position in FocalTherics during the first quarter valued at approximately $40,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source